Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Freed From Merck Deal, Portola Set To Move Betrixaban Forward With $89M Funding

This article was originally published in The Pink Sheet Daily

Executive Summary

Without a partner for its anticoagulant in an increasingly complex market, privately-held Portola takes $89 million in late-stage money to conduct Phase III trials on its own.


Related Content

As Some New Listings Thrive, IPO Pipeline Burgeons
The Antidote To Competition: Portola’s Rivals Fund Study On Class-Wide Anticoagulant Antidote
Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q4 2011
For Merck, Outcomes Trials Offer Fast Track To Payers
Bayer/J&J's Xarelto Approval For Stroke Prevention Sets Up Marketing Battle With Pradaxa
Astellas Discontinues Development Of Factor Xa Inhibitor Darexaban
Apixaban Shows Mortality Advantage, But Will It Survive FDA Scrutiny?
Back To The Drawing Board For Portola After Merck Returns Betrixaban
Portola Marries Factor Xa Clot Buster Off To Merck
Coulda, Shoulda? Sanofi's Skip On Portola Proves Clot-Buster Gain For Novartis


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts